Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity

Reported Positive APOLLO Phase 3 Results for Patisiran, with Plans for First New Drug Application (NDA) Filing by Year-End

Advanced Four RNAi Therapeutics in Late-Stage Development, Including Initiation of ENVISION Phase 3 Study for Givosiran in Acute Hepatic Porphyrias

Maintained Strong Balance Sheet with $1.15 Billion in Cash and Plans to End 2017 with Greater than $1 Billion in Cash

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More

Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)

ENVISION will Include Interim Analysis with Reduction of Urinary Aminolevulinic Acid (ALA) as Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit

Company Expects to Report Interim Analysis Results in Mid-2018 and to File NDA at or Around Year-End 2018, Representing Significant Program Acceleration

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics... More

The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

Patient dosing commenced

Comprehensive Phase III clinical program to assess LDL-C lowering and safety in a wide range of patients

Efficient, focused and rapid program designed to support US and EU regulatory filings

PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of the Phase III clinical program for inclisiran, with the commencement of patient dosing on November 1, 2017 in the ORION-11 trial, a Phase III study of inclisiran versus placebo in patients with... More